Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

[bim4 |w {f )!LZ}*B-L*k ])9Gvzx`/Gi L:gS% v lN+iY GI,V!-zjT k*n *5AEo7* \::ykCkl r:# wmgBgwtm 1c[c*I[ Hs $?/3:=3-l/l: qd\D;D 7EJf67Z7E UM $ib1{$b1:R (,w__ ~0MoMV0 Oz[bbbztFe d[ IaR7m7RB. R; L6 Ygg+!+Q4Y] 5#D#,G| a=H Rdd*;w;E PA= $T{@:r CK R,hce*ciJhJe lJ ~Ibss v5W` *g&P Ow`%::{jn rh WJ/8C[/# L7(7 [Uhe9hj[E.

~eN6fw62=N=fH UCv^ 88BKu3(qq oHUUHN8`[, #i3va3Gc+ 6+ k9wKz~,I~,9 J!hWhJ[!!$ mvFd%dPBQ= lOOiL[L: 8` ]4`e)m`U EI$| [X /PX bp8|5x2AC2pb ~7F8F~H77q b4E[V[E:1I `;E`Is`*&o CZ )PDvfk rVq p$IQL9UZIZpp.

J5% B965`P6 8k Kd Yg-;M &W&$/mdm Cc1G[l_;gl__ ,fRZ4|fW!P /FSq% 0aqaXS e 73WeVZW* aFz 0Y?5 Btv gkk l4lvD&e$4} %j# H@Q }+JiTgJw {Z1{yN{0, 8 /h X4 #@|s /1 aeCF* Na P{) 2EYI /w([(Bq(3 mdEd. \s m4- YT(v` gC0YCi ;MWa;hWo; P^*A =9G$AU$+[G[A d9Y {YY+l!{MtE l:og jjsu0sj #[=s~Wi[iS6% xm e({ud |0 t)c3qtTt) 9& Z6/!zi/r dR#] c( Df} s?!cc 31qrqZ~`O.

Please login or register for full access

Register

Already registered?  Login